Preclinical testing has suggested that AIR-001 increases functional AAT protein levels and could address the lung and liver manifestations of the disease.

The firm submitted data from the ALKOVE-1 trial, in which neladalkib shrunk tumors in 31 percent of patients and showed promising activity against CNS lesions.

In its third major acquisition in the past six weeks, Gilead is buying a company that will add NaPi2b- and 5T4-targeting agents to its portfolio.

The trial is evaluating how the disclosure of polygenic risk scores for cardiovascular disease affects patients' outcomes.

A study found that in about 10 percent of patients, WGS picked up on clinically actionable information other panels missed.